首页> Oncoimmunology> TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

导出 LinkOut

翻译打印收藏纠错

第一作者： Alice L,Hung

第一单位： Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.

作者： Alice L,Hung ^[1] ; Russell,Maxwell ^[1] ; Debebe,Theodros ^[2] ; Zineb,Belcaid ^[1] ; Dimitrios,Mathios ^[1] ; Andrew S,Luksik ^[1] ; Eileen,Kim ^[1] ; Adela,Wu ^[1] ; Yuanxuan,Xia ^[1] ; Tomas,Garzon-Muvdi ^[1] ; Christopher,Jackson ^[1] ; Xiaobu,Ye ^[1] ; Betty,Tyler ^[1] ; Mark,Selby ^[3] ; Alan,Korman ^[3] ; Bryan,Barnhart ^[3] ; Su-Myeong,Park ^[4] ; Je-In,Youn ^[5] ; Tamrin,Chowdhury ^[6] ; Chul-Kee,Park ^[6] ; Henry,Brem ^[1] ; Drew M,Pardoll ^[7] ; Michael,Lim ^[1]

作者单位： Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA. ^[1] Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.;Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA. ^[2] Bristol-Myers Squibb, New York, NY, USA. ^[3] Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea. ^[4] Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.;Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. ^[5] Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. ^[6] Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA. ^[7]

关键词 CD155 GBM PD-1 PVR TIGIT checkpoint inhibitor dendritic cell glioma immunotherapy

DOI 10.1080/2162402X.2018.1466769

PMID 30221069

发布时间 2021-11-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交